Usefulness of cytokeratin -19, galectin-3, and hector battifora mesothelial-1 in the diagnosis of benign and malignant thyroid nodules

Clinical Laboratory

Volumn 58, Issue 7-8, 2012, Pages 673-680

  Cui, Wenli ^a   Sang, Wei ^a   Zheng, Shutao ^a   Ma, Yuqing ^a   Liu, Xia ^a   Zhang, Wei ^a  

^a XINJIANG MEDICAL UNIVERSITY   (China)

Author keywords

CK 19; Gal 3; HBME 1; Thyroid nodule

Indexed keywords

ANTIBODY; CYTOKERATIN 19; GALECTIN 3; HECTOR BATTIFORA MESOTHELIAL 1 PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; GROUPS BY AGE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; NODULAR GOITER; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; THYROID ADENOMA; THYROID FOLLICULAR CARCINOMA; THYROID NODULE; THYROID PAPILLARY CARCINOMA; THYROID TUMOR; TUMOR DIAGNOSIS; TUMOR VOLUME;

GALECTIN 3; GOITER, NODULAR; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-19; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84866094552     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: 10.7754/Clin.Lab.2011.110917     Document Type: Article

References (13)

1. Singer PA, Cooper DS, Daniels GH, et al. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. Arch Intern Med 1996;156:2165-72.
2. Baloch ZW, Gupta PK, Yu GH, et al. Follicular variant of papillary carcinoma. Cytologic and histologic correlation. Am J Clin Pathol 1999;111:216-22.
3. Baloch ZW, LiVolsi VA. The quest for a magic tumor marker. Am J Clin Pathol 2002;118:165-6.
4. Sahoo S, Hoda SA, Rosai J, et al. Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma. Am J Clin Pathol 2001;116:696-702.
5. Weber KB, Shroyer KR, Heinz DE, et al. The use of a combination of Galectin-3 and Thyroid peroxidase for the diagnosis and prognosis of thyroid cancer. Am J Clin Pathol 2004;122:524-31.
6. Scognamiglio T, Hyjek E, Kao J, et al. Diagnostic usefulness of HBME-1, Galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. Am J Clin Pathol 2006;126:700-8.
7. Liu YY, Morreau H, Kievit J, et al. Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome prolieferator-activated receptor-γ, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma. Eur J Endocrinol 2008;158:375-84.
8. Cheung CC, Ezzat S, Freeman JL, et al. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol 2001;14:338-42.
9. Prasad ML, Pellegata NS, Huang Y, et al. Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol 2005;18:48-57.
10. de Matos PS, Ferreira AP, de Oliveira Facuri F, et al. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology 2005;47:391-401.
11. Martins L, Matsuo SE, Ebina KN, Kulcsar MA, et al. Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyoid tumors. J Clin Endocrinol Meta 2002;87:4806-10.
12. Kovacs RB, Foldes J, Winkler G, Bodo M, et al. The investigation of galectin-3 in disease of the thyroid gland. Eur J Endocrinol 2003;149:449-53.
13. Nasr MR, Mukhopadhyay S, Zhang S, et al. Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: utility of HBME1 combined with CK19 immunostaining. Mod Pathol 2006;19:1631-7.